Eleanor F. Harrison
University of Nottingham
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eleanor F. Harrison.
PLOS Medicine | 2017
Kim S Thomas; Lucy Bradshaw; Tracey Sach; Jonathan Batchelor; Sandra Lawton; Eleanor F. Harrison; Rachel H. Haines; Amina Ahmed; Hywel C. Williams; Taraneh Dean; Nigel Burrows; Ian Pollock; Joanne Llewellyn; Clare Crang; J. Grundy; Juliet Guiness; Andrew Gribbin; Eleanor Mitchell; Fiona Cowdell; Sara J. Brown; Alan A Montgomery
Background The role of clothing in the management of eczema (also called atopic dermatitis or atopic eczema) is poorly understood. This trial evaluated the effectiveness and cost-effectiveness of silk garments (in addition to standard care) for the management of eczema in children with moderate to severe disease. Methods and findings This was a parallel-group, randomised, controlled, observer-blind trial. Children aged 1 to 15 y with moderate to severe eczema were recruited from secondary care and the community at five UK medical centres. Participants were allocated using online randomisation (1:1) to standard care or to standard care plus silk garments, stratified by age and recruiting centre. Silk garments were worn for 6 mo. Primary outcome (eczema severity) was assessed at baseline, 2, 4, and 6 mo, by nurses blinded to treatment allocation, using the Eczema Area and Severity Index (EASI), which was log-transformed for analysis (intention-to-treat analysis). A safety outcome was number of skin infections. Three hundred children were randomised (26 November 2013 to 5 May 2015): 42% girls, 79% white, mean age 5 y. Primary analysis included 282/300 (94%) children (n = 141 in each group). The garments were worn more often at night than in the day (median of 81% of nights [25th to 75th centile 57% to 96%] and 34% of days [25th to 75th centile 10% to 76%]). Geometric mean EASI scores at baseline, 2, 4, and 6 mo were, respectively, 9.2, 6.4, 5.8, and 5.4 for silk clothing and 8.4, 6.6, 6.0, and 5.4 for standard care. There was no evidence of any difference between the groups in EASI score averaged over all follow-up visits adjusted for baseline EASI score, age, and centre: adjusted ratio of geometric means 0.95, 95% CI 0.85 to 1.07, (p = 0.43). This confidence interval is equivalent to a difference of −1.5 to 0.5 in the original EASI units, which is not clinically important. Skin infections occurred in 36/142 (25%) and 39/141 (28%) of children in the silk clothing and standard care groups, respectively. Even if the small observed treatment effect was genuine, the incremental cost per quality-adjusted life year was £56,811 in the base case analysis from a National Health Service perspective, suggesting that silk garments are unlikely to be cost-effective using currently accepted thresholds. The main limitation of the study is that use of an objective primary outcome, whilst minimising detection bias, may have underestimated treatment effects. Conclusions Silk clothing is unlikely to provide additional benefit over standard care in children with moderate to severe eczema. Trial registration Current Controlled Trials ISRCTN77261365
British Journal of Dermatology | 2018
E.V. Wake; Jonathan Batchelor; Sandra Lawton; Kim S Thomas; Eleanor F. Harrison; Fiona Cowdell
Many children suffer with skin diseases but to date most dermatological research has been done ‘on’ rather than ‘with’ children; in this study we actively sought the experiences of children and young people. Atopic eczema (AE) is a chronic, itchy, inflammatory skin condition that affects around 20% of children and can impact on the health and wellbeing of children and their families. The role of specialist clothing in the management of AE is poorly understood.
The Lancet Diabetes & Endocrinology | 2018
Frances L. Game; William Jeffcoate; Lise Tarnow; Judith L. Jacobsen; Diane Whitham; Eleanor F. Harrison; Sharon Ellender; Deborah Fitzsimmons; Magnus Löndahl; Ketan Dhatariya; Harvey Chant; Gill Spyer; Mollie Donohoe; Elizabeth Uchegbu; Donald Whitelaw; Rahul Nayar; Peter Rossing; Hans Gottlieb; Morton Michelsen; Anna Marie Nielsen; Kim Houlind; Jan Tind Sørensen; Eskild Henneberg; Bo Barker Jørgensen; Kilimangalam Narayanan; Marie-France Kong; Ammar Tarik; Rajiv Gandhi; Christian Hariman; Victor Oguntolu
BACKGROUND The LeucoPatch device uses bedside centrifugation without additional reagents to generate a disc comprising autologous leucocytes, platelets, and fibrin, which is applied to the surface of the wound. We aimed to test the effectiveness of LeucoPatch on the healing of hard-to-heal foot ulcers in people with diabetes. METHODS This was a multicentre, international, observer-masked, randomised controlled trial of people with diabetes and a hard-to-heal foot ulcer done in 32 specialist diabetic foot clinics in three countries (UK, Denmark, and Sweden). After a 4-week run-in period, those with a reduction in ulcer area of less than 50% were randomly allocated (1:1) by computer-generated, web-based randomisation (block sizes of two, four, and six) to either prespecified good standard care alone or care plus weekly application of LeucoPatch. The primary outcome was the proportion of ulcers that healed within 20 weeks assessed in the intention-to-treat population (all participants with post-randomisation data collected), defined as complete epithelialisation (confirmed by an observer who was masked to randomisation group), and remained healed for 4 weeks. This trial is registered with the ISRCTN registry, number 27665670, and ClinicalTrials.gov, number NCT02224742. FINDINGS Between Aug 30, 2013, and May 3, 2017, 269 participants were randomly allocated to receive treatment (137 to receive standard care and 132 to receive LeucoPatch). The mean age was 61·9 years (SD 11·6), 217 (82%) were men, and 222 (83%) had type 2 diabetes. In the LeucoPatch group, 45 (34%) of 132 ulcers healed within 20 weeks versus 29 (22%) of 134 ulcers in the standard care group (odds ratio 1·58, 96% CI 1·04-2·40; p=0·0235) by intention-to-treat analysis. Time to healing was shorter in the LeucoPatch group (p=0·0246) than in the standard care group. No difference in adverse events was seen between the groups. The most common serious adverse event (SAE) was diabetic foot infection (24 events in the LeucoPatch group [24% of all SAEs] and 20 in the standard care group [27% of all SAEs]. There were no device-related adverse events. INTERPRETATION The use of LeucoPatch is associated with significant enhancement of healing of hard-to-heal foot ulcers in people with diabetes. FUNDING Reapplix ApS.
British Journal of Dermatology | 2017
E.V. Wake; Jonathan Batchelor; Sandra Lawton; Kim S Thomas; Eleanor F. Harrison; Fiona Cowdell
Many children suffer with skin diseases but to date most dermatological research has been done ‘on’ rather than ‘with’ children; in this study we actively sought the experiences of children and young people. Atopic eczema (AE) is a chronic, itchy, inflammatory skin condition that affects around 20% of children and can impact on the health and wellbeing of children and their families. The role of specialist clothing in the management of AE is poorly understood.
British Journal of Dermatology | 2017
E.V. Wake; Jonathan Batchelor; Sandra Lawton; Kim S Thomas; Eleanor F. Harrison; Fiona Cowdell
Many children suffer with skin diseases but to date most dermatological research has been done ‘on’ rather than ‘with’ children; in this study we actively sought the experiences of children and young people. Atopic eczema (AE) is a chronic, itchy, inflammatory skin condition that affects around 20% of children and can impact on the health and wellbeing of children and their families. The role of specialist clothing in the management of AE is poorly understood.
Trials | 2015
Eleanor F. Harrison; Rachel H. Haines; Fiona Cowdell; Tracey Sach; Taraneh Dean; Ian Pollock; Nigel Burrows; H Buckley; Jonathan Batchelor; Hywel C. Williams; Sandra Lawton; Sara J. Brown; Lucy Bradshaw; Amina Ahmed; Alan A Montgomery; Eleanor Mitchell; Kim S Thomas
Health Technology Assessment | 2017
Kim S Thomas; Lucy Bradshaw; Tracey Sach; Fiona Cowdell; Jonathan Batchelor; Sandra Lawton; Eleanor F. Harrison; Rachel H. Haines; Amina Ahmed; Taraneh Dean; Nigel Burrows; Ian Pollock; H Buckley; Hywel C. Williams; Joanne Llewellyn; Clare Crang; Jane Grundy; Juliet Guiness; Andrew Gribbin; Eileen V Wake; Eleanor Mitchell; Sara J. Brown; Alan A Montgomery
Diabetes | 2018
Frances L. Game; William Jeffcoate; Lise Tarnow; Judith L. Jacobsen; Diane Whitham; Eleanor F. Harrison; Sharon Ellender; Magnus Löndahl
Value in Health | 2017
Tracey Sach; Emma McManus; Kim S Thomas; Alan A Montgomery; Eleanor F. Harrison; Hywel C. Williams
Trials | 2017
Eleanor F. Harrison; Wei Tan; Nicola Mills; Alexia Karantana; Kirsty Sprange; Lelia Duley; Daisy Elliott; Jane M Blazeby; William Hollingworth; Alan A Montgomery; T. R. C. Davis